Therapeutic potential of chemokine receptor antagonists for liver disease

Expert Review of Clinical Pharmacology

Volumn 4, Issue 4, 2011, Pages 503-513

  Sahin, Hacer ^a   Berres, Marie Luise ^a   Wasmuth, Hermann E ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

chemokine; chemokine receptor; functional murine model; human trial; liver disease; receptor antagonist

Indexed keywords

APLAVIROC; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR6; CHEMOKINE RECEPTOR CXCR7; CXCL9 CHEMOKINE; DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MARAVIROC; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; PLERIXAFOR; RANTES; SCAVENGER RECEPTOR D; SCAVENGER RECEPTOR D 6; SITAGLIPTIN; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; BASOPHIL; BILE DUCT LIGATION; BINDING AFFINITY; BONE MARROW TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL INFILTRATION; DENDRITIC CELL; DNA BINDING; DNA DEGRADATION; DRUG EFFICACY; EOSINOPHIL; GENE DELETION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HEPATITIS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; INFLAMMATORY DISEASE; KUPFFER CELL; LIVER CELL; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; MACROPHAGE; MAST CELL; MONOCYTE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; STELLATE CELL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; THROMBOCYTE;

ANIMALS; CHEMOKINES; HUMANS; LIGANDS; LIVER DISEASES; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 79960400868     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.24     Document Type: Review

References (99)

1. Sahin H, Trautwein C, Wasmuth HE. Functional role of chemokines in liver disease models. Nat. Rev. Gastroenterol. Hepatol. 7(12), 682-690 (2010).
2. Bonecchi R, Galliera E, Borroni EM, Corsi MM, Locati M, Mantovani A. Chemokines and chemokine receptors: an overview. Front. Biosci. 14, 540-551 (2009).
3. Colvin RA, Campanella GS, Sun J, Luster AD. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J. Biol. Chem. 279(29), 30219-30227 (2004). (Pubitemid 38937947)
4. Liu L, Callahan MK, Huang D, Ransohoff RM. Chemokine receptor CXCR3: an unexpected enigma. Curr. Top. Dev. Biol. 68, 149-181 (2005). (Pubitemid 43588858)
5. Weber C, Koenen RR. Fine-tuning leukocyte responses: towards a chemokine 'interactome'. Trends Immunol. 27(6), 268-273 (2006). (Pubitemid 43850403)
6. Proudfoot AE, Power CA, Schwarz MK. Anti-chemokine small molecule drugs: a promising future? Expert Opin. Investig. Drugs 19(3), 345-355 (2010).
7. Wasmuth HE, Tacke F, Trautwein C. Chemokines in liver inflammation and fibrosis. Semin. Liver Dis. 30, 215-225 (2010).
8. Pease JE, Horuk R. Chemokine receptor antagonists: part 1. Expert Opin. Ther. Pat. 19(1), 39-58 (2009).
9. Pease JE, Horuk R. Chemokine receptor antagonists: part 2. Expert Opin. Ther. Pat. 19(2), 199-221 (2009).
10. Seki E, De Minicis S, Gwak GY et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J. Clin. Invest. 119(7), 1858-1870 (2009).
11. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Invest. 90(1), 196-203 (1992).
12. Ajuebor MN, Hogaboam CM, Le T, Proudfoot AE, Swain MG. CCL3/MIP-1ais pro-inflammatory in murine T cell-mediated hepatitis by recruiting CCR1-expressing CD4+ T cells to the liver. Eur. J. Immunol. 34(10), 2907-2918 (2004). (Pubitemid 39430166)
13. Moreno C, Gustot T, Nicaise C et al. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology 42(4), 854-862 (2005). (Pubitemid 41401123)
14. Ajuebor MN, Wondimu Z, Hogaboam CM, Le T, Proudfoot AE, Swain MG. CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. Am. J. Pathol. 170(6), 1975-1988 (2007). (Pubitemid 47339271)
15. Goulding C, McManus R, Murphy A et al. The CCR5-d32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 54(8), 1157-1161 (2005). (Pubitemid 41025913)
16. Berres ML, Koenen RR, Rueland A et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J. Clin. Invest. 120(11), 4129-4140 (2010).
17. Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am. J. Physiol. Gastrointest. Liver Physiol. 285(5), G949-G958 (2003). (Pubitemid 37310074)
18. Sayana S, Khanlou H. Maraviroc: a new CCR5 antagonist. Expert Rev. Anti Infect. Ther. 7(1), 9-19 (2009).
19. Marra F, Grandaliano G, Valente AJ, Abboud HE. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. Hepatology 22(3), 780-787 (1995).
20. Ramm GA, Shepherd RW, Hoskins AC et al. Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology 49(2), 533-544 (2009).
21. Marra F, Valente AJ, Pinzani M, Abboud HE. Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines. J. Clin. Invest. 92(4), 1674-1680 (1993). (Pubitemid 23304529)
22. Seki E, De Minicis S, Osterreicher CH et al. TLR4 enhances TGF-b signaling and hepatic fibrosis. Nat. Med. 13(11), 1324-1332 (2007). (Pubitemid 350073596)
23. Kruglov EA, Nathanson RA, Nguyen T, Dranoff JA. Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts. Am. J. Physiol. 290(4), G765-G771 (2006).
24. Marra F, DeFranco R, Grappone C et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am. J. Pathol. 152(2), 423-430 (1998). (Pubitemid 28106388)
25. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19(1), 71-82 (2003). (Pubitemid 36859902)
26. Sozzani S, Luini W, Borsatti A et al. Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J. Immunol. 159(4), 1993-2000 (1997). (Pubitemid 127484190)
27. Loetscher P, Seitz M, Baggiolini M, Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J. Exp. Med. 184(2), 569-577 (1996). (Pubitemid 26324110)
28. Seki E, de Minicis S, Inokuchi S et al. CCR2 promotes hepatic fibrosis in mice. Hepatology 50(1), 185-197 (2009).
29. Zamara E, Galastri S, Aleffi S et al. Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. J. Hepatol. 46(2), 230-238 (2007). (Pubitemid 46001473)
30. Mitchell C, Couton D, Couty JP et al. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am. J. Pathol. 174(5), 1766-1775 (2009).
31. Karlmark KR, Weiskirchen R, Zimmermann HW et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 50(1), 261-274 (2009).
32. Yang SJ, IglayReger HB, Kadouh HC, Bodary PF. Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy. Diabetologia 52(5), 972-981 (2009).
33. Tamura Y, Sugimoto M, Murayama T et al. C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice. J. Atheroscl. Thromb. 17(3), 219-228 (2010).
34. Dagouassat M, Suffee N, Hlawaty H et al. Monocyte chemoattractant protein-1 (MCP-1)/CCL2 secreted by hepatic myofibroblasts promotes migration and invasion of human hepatoma cells. Int. J. Cancer 126(5), 1095-1108 (2010).
35. Mantovani A, Bonecchi R, Locati M. Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat. Rev. Immunol. 6(12), 907-918 (2006). (Pubitemid 44851733)
36. Graham GJ. D6 and the atypical chemokine receptor family: novel regulators of immune and inflammatory processes. Eur. J. Immunol. 39(2), 342-351 (2009).
37. Wiederholt T, von Westernhagen M, Zaldivar MM et al. Genetic variations of the chemokine scavenger receptor D6 are associated with liver inflammation in chronic hepatitis C. Hum. Immunol. 69(12), 861-866 (2008).
38. Berres ML, Trautwein C, Zaldivar MM et al. The chemokine scavenging receptor D6 limits acute toxic liver injury in vivo. Biol. Chem. 390(10), 1039-1045 (2009).
39. Levashova ZB, Sharma N, Timofeeva OA, Dome JS, Perantoni AO. ELR+-CXC chemokines and their receptors in early metanephric development. J. Am. Soc. Nephrol. 18(8), 2359-2370 (2007). (Pubitemid 47208110)
40. Lentsch AB, Kato A, Yoshidome H, McMasters KM, Edwards MJ. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology 32(2), 169-173 (2000). (Pubitemid 30614647)
41. Colletti LM, Kunkel SL, Walz A et al. Chemokine expression during hepatic ischemia/reperfusion-induced lung injury in the rat. The role of epithelial neutrophil activating protein. J. Clin. Invest. 95(1), 134-141 (1995).
42. Bertini R, Allegretti M, Bizzarri C et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc. Natl Acad. Sci. USA 101(32), 11791-11796 (2004). (Pubitemid 39095373)
43. Kuboki S, Shin T, Huber N et al. Hepatocyte signaling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia/reperfusion in mice. Hepatology 48(4), 1213-1223 (2008).
44. Clarke C, Kuboki S, Sakai N et al. CXC chemokine receptor-1 is expressed by hepatocytes and regulates liver recovery after hepatic ischemia/reperfusion injury. Hepatology 53(1), 261-271 (2011).
45. Bernhagen J, Krohn R, Lue H et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 13(5), 587-596 (2007). (Pubitemid 46828480)
46. Hori Y, Sato S, Yamate J et al. Immunohistochemical study of macrophage migration inhibitory factor in rat liver fibrosis induced by thioacetamide. Eur. J. Histochem. 47(4), 317-324 (2003).
47. Stefanovic L, Brenner DA, Stefanovic B. Direct hepatotoxic effect of KC chemokine in the liver without infiltration of neutrophils. Exp. Biol. Med. 230(8), 573-586 (2005). (Pubitemid 41233157)
48. Santodomingo-Garzon T, Han J, Le T, Yang Y, Swain MG. Natural killer T cells regulate the homing of chemokine CXC receptor 3-positive regulatory T cells to the liver in mice. Hepatology 49(4), 1267-1276 (2009).
49. Pesce J, Kaviratne M, Ramalingam TR et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J. Clin. Invest. 116(7), 2044-2055 (2006). (Pubitemid 44033328)
50. Shi Z, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc. Natl Acad. Sci. USA 94(20), 10663-10668 (1997). (Pubitemid 27430791)
51. Wynn TA. Fibrotic disease and the TH1/TH2 paradigm. Nat. Rev. Immunol. 4(8), 583-594 (2004).
52. Syrbe U, Siveke J, Hamann A. Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression? Springer Semin. Immunopathol. 21(3), 263-285 (1999). (Pubitemid 30011439)
53. Lasagni L, Francalanci M, Annunziato F et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 197(11), 1537-1549 (2003). (Pubitemid 36682550)
54. Eksteen B, Miles A, Curbishley SM et al. Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10. J. Immunol. 177(1), 593-603 (2006). (Pubitemid 43939173)
55. Curbishley SM, Eksteen B, Gladue RP, Lalor P, Adams DH. CXCR 3 activation promotes lymphocyte transendothelial migration across human hepatic endothelium under fluid flow. Am. J. Pathol. 167(3), 887-899 (2005). (Pubitemid 41216371)
56. Schrage A, Wechsung K, Neumann K et al. Enhanced T cell transmigration across the murine liver sinusoidal endothelium is mediated by transcytosis and surface presentation of chemokines. Hepatology 48(4), 1262-1272 (2008).
57. Wasmuth HE, Lammert F, Zaldivar MM et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 137(1), 309-319, 319.e1-3 (2009).
58. Jiang D, Liang J, Hodge J et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J. Clin. Invest. 114(2), 291-299 (2004). (Pubitemid 39071634)
59. Nakaya I, Wada T, Furuichi K et al. Blockade of IP-10/CXCR3 promotes progressive renal fibrosis. Nephron. Exp. Nephrol. 107(1), e12-e21 (2007). (Pubitemid 47355797)
60. Rosenblum JM, Zhang QW, Siu G et al. CXCR3 antagonism impairs the development of donor-reactive, IFN-g-producing effectors and prolongs allograft survival. Transplantation 87(3), 360-369 (2009).
61. Barbi J, Oghumu S, Rosas LE et al. Lack of CXCR3 delays the development of hepatic inflammation but does not impair resistance to Leishmania donovani. J. Infect. Dis. 195(11), 1713-1717 (2007). (Pubitemid 46799230)
62. Bonacchi A, Romagnani P, Romanelli RG et al. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J. Biol. Chem. 276(13), 9945-9954 (2001).
63. Pockros PJ, Jeffers L, Afdhal N et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-g1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 45(3), 569-578 (2007). (Pubitemid 46450609)
64. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 16(6), 593-609 (2005). (Pubitemid 41505519)
65. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J. Hepatol. 50(3), 604-620 (2009).
66. Hintermann E, Bayer M, Pfeilschifter JM, Luster AD, Christen U. CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. J. Autoimmun. 35(4), 424-435 (2010).
67. Zeremski M, Petrovic LM, Chiriboga L et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 48(5), 1440-1450 (2008).
68. Romero AI, Lagging M, Westin J et al. Interferon (IFN)-g-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-a2a and ribavirin for chronic hepatitis C virus infection. J. Infect. Dis. 194(7), 895-903 (2006). (Pubitemid 44454074)
69. Tan AT, Koh S, Goh W et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J. Hepatol. 52(3), 330-339 (2010).
70. Nishioji K, Okanoue T, Itoh Y et al. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune increase of its mRNA expression in hepatocytes. Clin. Exp. Immunol. 123(2), 271-279 (2001). (Pubitemid 32174779)
71. Diago M, Castellano G, Garcia-Samaniego J et al. Association of pretreatment serum interferon g inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 55(3), 374-379 (2006). (Pubitemid 43268277)
72. Berres ML, Trautwein C, Schmeding M et al. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. Hepatology 53(2), 596-603 (2011).
73. Casrouge A, Decalf J, Ahloulay M et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J. Clin. Invest. 121(1), 308-317 (2011).
74. Zaldivar MM, Pauels K, von Hundelshausen P et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 51(4), 1345-1353 (2010).
75. von Hundelshausen P, Koenen RR, Sack M et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 105(3), 924-930 (2005). (Pubitemid 40170856)
76. Mueller A, Meiser A, McDonagh EM et al. CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. J. Leukoc. Biol. 83(4), 875-882 (2008). (Pubitemid 351959867)
77. Tsutsumi H, Tanaka T, Ohashi N et al. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolymers 88(2), 279-289 (2007). (Pubitemid 46661507)
78. Balakin KV, Ivanenkov YA, Savchuk NP. Compound library design for target families. Methods Mol. Biol. 575, 21-46 (2009).
79. Flomenberg N, Devine SM, Dipersio JF et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106(5), 1867-1874 (2005). (Pubitemid 41208607)
80. Mark AL, Sun Z, Warren DS et al. Stem cell mobilization is life saving in an animal model of acute liver failure. Ann. Surg. 252(4), 591-596 (2010).
81. Wald O, Pappo O, Safadi R et al. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur. J. Immunol. 34(4), 1164-1174 (2004). (Pubitemid 39255996)
82. Naumann U, Cameroni E, Pruenster M et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PloS One 5(2), e9175 (2010).
83. Miao Z, Luker KE, Summers BC et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl Acad. Sci. USA 104(40), 15735-15740 (2007). (Pubitemid 350035369)
84. Zheng K, Li HY, Su XL et al. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J. Exp. Clin. Cancer Res. 29, 31 (2010).
85. Heydtmann M, Lalor PF, Eksteen JA, Hubscher SG, Briskin M, Adams DH. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J. Immunol. 174(2), 1055-1062 (2005). (Pubitemid 40094302)
86. Jafri M, Donnelly B, Bondoc A, Allen S, Tiao G. Cholangiocyte secretion of chemokines in experimental biliary atresia. J. Pediatr. Surg. 44(3), 500-507 (2009).
87. Omenetti A, Syn WK, Jung Y et al. Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. Hepatology 50(2), 518-527 (2009).
88. Koenen RR, von Hundelshausen P, Nesmelova IV et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat. Med. 15(1), 97-103 (2009).
89. Villa P, Triulzi S, Cavalieri B et al. The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Mol. Med. 13(3-4), 125-133 (2007). (Pubitemid 46944954)
90. Zhao Q. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J. Leukoc. Biol. 88(1), 41-55 (2010).
91. Ramos CD, Canetti C, Souto JT et al. MIP-1a[CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential release of TNF-aand LTB4. J. Leukoc. Biol. 78(1), 167-177 (2005). (Pubitemid 40979955)
92. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev. 12(4), 313-335 (2001). (Pubitemid 32851745)
93. Bonecchi R, Polentarutti N, Luini W et al. Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-g in human neutrophils. J. Immunol. 162(1), 474-479 (1999). (Pubitemid 29018956)
94. Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat. Rev. Drug Discov. 8(1), 23-33 (2009).
95. Horvath C, Welt FG, Nedelman M, Rao P, Rogers C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ. Res. 90(4), 488-494 (2002). (Pubitemid 34633920)
96. Gladue RP, Cole SH, Roach ML et al. The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice. J. Immunol. 176(5), 3141-3148 (2006).
97. Li AR, Johnson MG, Liu J et al. Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists. Bioorg. Med. Chem. Lett. 18(2), 688-693 (2008).
98. Yang XD, Corvalan JR, Wang P, Roy CM, Davis CG. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J. Leukoc. Biol. 66(3), 401-410 (1999). (Pubitemid 29439246)
99. Oo YH, Shetty S, Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. Dig. Dis. 28(1), 31-44 (2010).